sanofi

4th August 2026

To

The Secretary	The Secretary
BSE Limited	The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza, C-1, Block G,
Dalal Street	Bandra-Kurla Complex, Bandra (E)
Mumbai 400 001	Mumbai 400 051
Scrip Code: 500674	Symbol: SANOFI

Sub: Outcome of the Board Meeting of the Company

Dear Sirs/Madam,

We refer to our intimation dated 20th July 2026, we hereby inform you that the Board of Directors at its meeting held today i.e., Tuesday, 4th August 2026, *inter-alia:*

1. Considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026.

   Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Results for the quarter and half year ended 30th June 2026, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). A press release in this regard has also been enclosed.

   Extract of the aforesaid Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations. The aforesaid Financial Results will also be available on the Company's website on Financial results - Sanofi India.

2. Pursuant to Regulation 30 of the Listing Regulations, the Board of Directors have approved:

a. Re-constitution of the following Committees with effect from 1st October 2026:

i. Stakeholders Relationship Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Mr. Siraj Chaudhry	Independent Director	Chairman
2	Mr. Deepak Arora	Managing Director	Member
3	Ms. Sudipta Chakraborty	Whole Time Director	Member

sanofi

ii. Risk Management Committee:

Sr No	Name of the Member	Category	Position in the Committee
1	Ms. Rajani Kesari	Independent Director	Chairperson
2	Mr. Siraj Chaudhry	Independent Director	Member
3	Mr. Deepak Arora	Managing Director	Member
4	Mr. Mahadev Gawade	Whole Time Director	Member

b. Pursuant to the Regulation 30(5) of the Listing Regulations, in view of stepping down of Mr. Rachid Ayari as Whole Time Director and Chief Financial Officer with effect from the close of business hours on 30th September 2026, his name will be deleted from the list of Key Managerial Personnels authorised to determine materiality of an event or information and making disclosures to the Stock Exchanges.

The meeting of Board of Directors commenced at 4:00 p.m. and concluded at 6:58 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

Haresh Bachubhai Vala
Digitally signed by Haresh Bachubhai Vala
Date: 2026.08.04 20:07:30 +05'30'

Haresh Vala
Company Secretary and Compliance Officer
Membership No.: A18246

Encl: a/a

Press Release

Sanofi India delivers strong Q2 2026 performance, Led by double digit growth in Diabetes Portfolio and a Robust Profit Momentum

Mumbai, August 4th, 2026

Sanofi India Limited announced its financial results for the quarter ended on June 30th, 2026, reporting **domestic net sales** growth of **8%** and total net sales growth of **6%** compared to the second quarter of 2025.

The **Insulin portfolio** continued its strong trajectory, delivering **double-digit growth of 14%** for the second consecutive quarter, reinforcing Sanofi's leadership position in the basal analog market with a **58% value market share and 61% volume market share***. Growth was powered by Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®, the premium offering in the premix diabetes space.

The **public sector business** accelerated by **70%**, with the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, further strengthening Sanofi's footprint in the diabetes injectable space.

Strategic partnerships in Cardiovascular, Oral anti-Diabetes and Central Nervous System segments have established a strong foundation, meeting expectations for market reach expansion. **Partnership revenues grew 2%** in Q2 2026, with continued return on investment from an expanded commercial footprint

Export sales remained broadly stable, demonstrating the resilience of Sanofi India's international operations amid global headwinds.

Profits before tax and exceptional items increased 19% to INR 112 crores, compared to INR 94 crores in the second quarter 2025. Profit before tax as a percentage of net sales improved to **27% in Q2 2026**, up from 24% in Q2 2025.

This improvement reflects a favorable product mix and disciplined cost management through operational efficiencies, with **operating expenses** (employee cost + other expenses) **declining 5%** compared to the second quarter of 2025.

Deepak Arora
Managing Director

"Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double-digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business.

Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a modernized go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long-term value creation is firmly in place.

As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents."

* Source for market share: IQVIA MAT June 2026

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices from 2019-2024, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/india, LinkedIn and X.

Media Relations
Vinifer Gandhi | vinifer.gandhi@sanofi.com

Review Report

To
The Board of Directors
Sanofi India Limited
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the "Company") for the quarter ended June 30, 2026 and the year to date results for the period January 01, 2026 to June 30, 2026, the Unaudited Statement of Assets and Liabilities as on that date and the Unaudited Statement of Cash Flows for the half-year ended on that date which are included in the accompanying 'Statement of Unaudited Financial Results for the quarter and half year ended June 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

ARUNKUMAR RAMDAS
Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.08.04 20:01:12 +05'30'

Arunkumar Ramdas
Partner
Membership Number: 112433
UDIN: 26112433VMUERB4705

Place: Mumbai
Date: August 04, 2026

Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park, Nesco Complex Gate No. 3 Western Express Highway, Goregaon East, Mumbai 400 063
T: +91 (22) 61197808

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

SANOFI INDIA LIMITED

Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846
Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED JUNE 30, 2026

₹ in Million

Particulars	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Unaudited)	Quarter ended 30.06.2025 (Unaudited)	Half year ended 30.06.2026 (Unaudited)	Half year ended 30.06.2025 (Unaudited)	Year ended 31.12.2025 (Audited)
1. Revenue from Operations	4,377	4,723	4,063	9,100	9,422	18,374
2. Other Income	62	44	87	106	120	197
3. Total Income (1+2)	4,439	4,767	4,150	9,206	9,542	18,571
4. Expenses						
(a) Cost of Materials Consumed	573	503	621	1,076	1,378	2,464
(b) Purchases of stock-in-trade	1,589	1,482	356	3,071	1,197	5,140
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	90	358	1,110	448	1,917	1,368
(d) Employee benefits expense	446	428	449	874	987	1,853
(e) Finance costs	3	3	4	6	7	17
(f) Depreciation and amortisation expense	89	90	91	179	187	373
(g) Other expenses	526	524	578	1,050	1,275	2,636
Total Expenses	3,316	3,388	3,209	6,704	6,948	13,851
5. Profit before exceptional item and tax (3-4)	1,123	1,379	941	2,502	2,594	4,720
6. Exceptional item (Refer note 3)	-	-	-	-	-	(273)
7. Profit before tax (5+6)	1,123	1,379	941	2,502	2,594	4,447
8. Income tax expense						
Current Tax	297	343	250	640	707	1,229
Deferred Tax	(9)	10	(4)	1	(3)	(49)
9. Profit for the period /year (7-8)	835	1,026	695	1,861	1,890	3,267
10. Other comprehensive income (OCI) (Net of Tax)	-	-	-	-	-	17
11. Total comprehensive income for the period/year (9+10)	835	1,026	695	1,861	1,890	3,284
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	7,262
14. Basic and diluted earnings per share (not annualised) (in ₹)	36.26	44.55	30.18	80.81	82.07	141.85

ARUNKUMA R RAMDAS Digitally signed by ARUNKUMAR RAMDAS Date: 2026.08.04 20:01:41 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026

Deepak Arora Digitally signed by Deepak Arora Date: 2026.08.04 19:44:02 +05'30'

SANOFI INDIA LIMITED
UNAUDITED STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

Particulars	As at June 30, 2026 Unaudited	As at December 31, 2025 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	2,392	2,493
Capital work in progress	192	116
Right-of-use assets	508	541
Intangible assets	7	7
Financial assets		
Other financial assets	88	68
Income tax assets (net)	1,159	1,212
Deferred tax assets (net)	43	44
Other non-current Assets	35	61
Total non-current assets	**4,424**	**4,542**
Current Assets		
Inventories	3,112	3,116
Financial assets		
(i) Trade receivables	2,321	1,767
(ii) Cash and cash equivalents	3,590	2,629
(iii) Bank Balances other than (ii) above	97	120
(iv) Loans	3	9
(v) Other financial Assets	53	28
Other current assets	474	337
Total current assets	**9,650**	**8,006**
TOTAL ASSETS	**14,074**	**12,548**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	230	230
Other equity		
Reserves and surplus	8,030	7,262
Total equity	**8,260**	**7,492**
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Lease liabilities	108	137
Provisions - employee benefit obligations	5	5
Total non-current liabilities	**113**	**142**
Current liabilities		
Financial liabilities		
(i) Lease liabilities	39	41
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	87	100
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,653	1,840
(iii) Other financial liabilities	485	610
Provisions - others	1,075	1,135
Provisions - employee benefit obligations	250	198
Current tax liabilities (net)	1,091	957
Other current liabilities	21	33
Total current liabilities	**5,701**	**4,914**
Total liabilities	**5,814**	**5,056**
TOTAL EQUITY AND LIABILITIES	**14,074**	**12,548**

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.08.04 20:02:00 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026

Deepak Arora

Digitally signed by Deepak Arora
Date: 2026.08.04 19:44:28 +05'30'

SANOFI INDIA LIMITED
UNAUDITED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED JUNE 30, 2026

₹ in Million

Particulars	Half year ended June 30, 2026 (Unaudited)	Half year ended June 30, 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	**2,502**	**2,594**
Adjustment for :		
Depreciation and amortisation expenses	179	187
Unrealised exchange loss / (gain) (net)	4	(4)
(Gain) on sale of property, plant and equipment	(5)	(1)
(Gain) on termination/retirement of lease (net)	*	(11)
Finance costs	6	7
Interest income	(78)	(68)
Share based payment (net)	12	19
Provision for bad and doubtful debts (net)	(6)	11
Provision for doubtful advances and deposits (net)	(6)	-
Operating profit before working capital changes	**2,608**	**2,734**
Adjustments for (increase) / decrease in operating assets		
Non-current financial assets	(14)	6
Other non-current assets	*	*
Inventories	4	2,281
Trade receivables	(558)	698
Current financial assets, loans and other bank balances	4	392
Other current assets	(137)	219
Adjustments for increase / (decrease) in operating liabilities		
Provisions - employee benefit obligations	52	(9)
Trade payables	806	(2,640)
Current financial liabilities	(126)	(213)
Other current liabilities, loans and provisions - others	(72)	(130)
Cash generated from operations	**2,567**	**3,338**
Taxes paid (Net of refunds)	(453)	(428)
Net Cash inflow from operating activities (A)	**2,114**	**2,910**
Cash flow from Investing activities		
Sale proceeds of property, plant and equipment	9	5
Interest received	78	68
Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress	(110)	(144)
Net cash outflow from investing activities (B)	**(23)**	**(71)**
Cash flow from financing activities		
Principal elements of lease payments	(19)	(24)
Interest paid	(6)	(7)
Dividend paid	(1,105)	(2,695)
Net cash outflow from financing activities (C)	**(1,130)**	**(2,726)**
Net increase in cash and cash equivalents (A+B+C)	**961**	**113**
Effect of Exchange differences on cash and cash equivalents held in foreign currency	*	*
Cash and Cash Equivalents at the beginning of the period	2,629	2,838
Cash and Cash Equivalents at the end of the period	**3,590**	**2,951**
Non- cash financing and investing activities (D)		
Acquisition of Right-of-use assets	-	131
<u>Components of Cash and Cash Equivalents</u>		
Cash and Cash Equivalents	**3,590**	**2,951**

* denotes figure less than a million.

ARUNKUMAR RAMDAS
Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.08.04 20:02:20 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026

Deepak Arora
Digitally signed by Deepak Arora
Date: 2026.08.04 19:44:57 +05'30'

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 04, 2026. The statutory auditors have carried out a limited review of the above results for the quarter and half year ended June 30, 2026.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.

3. Exceptional items relate to personnel separation costs of ₹273 million for the year ended December 31, 2025.

4. The Company has a single business segment namely 'Pharmaceutical Business'.

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.08.04 20:02:37 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated August 04, 2026

SANOFI INDIA LIMITED

Deepak Arora

Digitally signed by Deepak Arora
Date: 2026.08.04 19:45:30 +05'30'

DEEPAK ARORA
MANAGING DIRECTOR
DIN: 07495638

August 04, 2026